The vertical-style superomedial pedicle reduction mammaplasty is safe and effective for a wide range of symptomatic macromastia. The nipple-areola complex can be safely transposed, even in patients with larger degrees of macromastia, with no episodes of nipple necrosis. The adjunctive use of liposuction should be considered safe. Last, revision rates were low, correlating with a high level of patient satisfaction.

No abstract

were found to be significantly more common in those who had recurrence or died of their disease (24% vs. 4%; adjusted p¼0.02). Survival analysis showed patients with KDM5C having statistically significant inferior cancer-specific survival (adjusted p¼<0.01) and a trend for inferior survival in those with SETD2 mutations (adjusted p¼0.11) (Figure 1).CONCLUSIONS: We identified mutations in SRMs that are associated with recurrence and lethality. The strongest association was seen with KDM5Cmutations. Use of these potential genomic biomarkers may improve risk stratification of patients with SRMs and for those who may be appropriate for AS. Prospective evaluation of these markers is needed. Source ofFunding: Funded in part by the Sidney Kimmel Center for Prostate and Urologic Cancers and the National Cancer Institute Training Grant T32 CA082088 (BM MG). Clinical and Translational Science Center at Weill Cornell Medical Center UL1TR00457 (BM).

Background and Objectives Prior small studies have reported a possible association between renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GISTs). In the largest known series, our objective was to describe the prevalence of RCC among patients with GISTs over 26 years at Memorial Sloan Kettering Cancer Center (MSKCC). Methods We retrospectively reviewed MSKCC’s prospectively maintained sarcoma and RCC databases and identified all patients with both RCC and GIST between 1980 and 2016. Demographic and clinicopathological characteristics were obtained. Results 9/405 (2.2%) GIST patients were identified with RCC, with a mean follow-up of 9.2 [Range 3.8 – 28.4] years. 5/9 (55.6%) patients had RCC and GIST diagnosis within 6 months of each other. Mean RCC tumor size was 3.0 [Range 1.8 – 8] cm and 8/9 (88.9%) patients were RCC stage 1. 4/9 (44.4%) patients had papillary RCC (pRCC) histology, 5/9 (55.6%) had additional alternative malignancies, and 4/9 (44.4%) had primary small bowel GIST. Conclusions Our series suggests a possible association of RCC with GISTs. In addition, we found a high frequency of pRCC histology, alternative malignancies and small bowel GISTs in co-occurring RCC-GIST patients. Further investigation to identify genetic mutations, in this population, would assist in surveillance and treatment.